Amgen (AMGN) Tops Q4 EPS by 10c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Amgen Reports Fourth Quarter And Full Year 2016 Financial Results
February 2, 2017 4:21 PM ESTTHOUSAND OAKS, Calif., Feb. 2, 2017 /PRNewswire/ --Â Amgen (NASDAQ: AMGN) today announced financial results for the fourth quarter and full year of 2016. Key results include:
For the fourth quarter, total revenues increased 8 percent versus the fourth quarter of 2015 to $6.0 billion. Product sales grew 6 percent driven by Enbrel® (etanercept), Prolia® (denosumab), Repatha® (evolocumab) and KYPROLIS® (carfilzomib). For the full year, total revenues increased 6 percent to $23.0 billion, with 5 percent product sales growth. GAAP earnings per share (EPS) increased 9 percent in the fourth quarter to $2.59... More